CRM1 INHIBITORS SENSITIZE MULTIPLE MYELOMA CELLS TO TOPOISOMERASE II AND PROTEASOME INHIBITORS

Catriona HM Jamieson

(PQC2) Niche-responsive RNA editing by ADAR1 in dormant multiple myeloma initiating cell maintenance

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies Pathology

Elad Ziv

Influence of germ line genetic variation on myeloma progression and survival

Multiple myeloma and immunoproliferative diseases

Pathology Hematology and hematologic malignancies

Jing Yang

Targeting adipocyte-secreted chemerin for chemotherapy resistance in myeloma

Multiple myeloma and immunoproliferative diseases

Jens G Lohr

Determining the mutational landscape of circulating multiple myeloma cells

Multiple myeloma and immunoproliferative diseases

Pathology

Ralph D Sanderson

Heparanase Regulation of Myeloma Metastasis: Mechanism and Therapy

Multiple myeloma and immunoproliferative diseases

Hematology and hematologic malignancies

Robert Zygmunt Orlowski

Role of TJP1 in Sensitivity and Resistance to Proteasome Inhibitors in Myeloma

Multiple myeloma and immunoproliferative diseases

Irene M. Ghobrial

The role of miRNA15a and 16-1 in Multiple Myeloma

Multiple myeloma and immunoproliferative diseases

Kenneth C Anderson

Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications

Multiple myeloma and immunoproliferative diseases

Pathology Hematology and hematologic malignancies

Sarah A Holstein

Rab Geranylgeranylation: a Novel Therapeutic Target in Multiple Myeloma

Multiple myeloma and immunoproliferative diseases